within Pharmacolibrary.Drugs.ATC.A;

model A01AB09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 10.4 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,
    adminCount     = 1,
    Vd             = 0.0014,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0006166666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Miconazole is an imidazole antifungal agent used to treat fungal infections, particularly those caused by Candida and dermatophytes. It is commonly employed for oral, oropharyngeal, and topical fungal infections. Miconazole is approved and prescribed for oropharyngeal candidiasis (oral thrush) as well as skin mycoses, and is widely available in topical and oral gel formulations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for adult healthy volunteers after repeated oral administration of miconazole oral gel.</p><h4>References</h4><ol><li><p>Hynninen, VV, et al., &amp; Laine, K (2009). Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib. <i>European journal of clinical pharmacology</i> 65(1) 89–95. DOI:<a href=&quot;https://doi.org/10.1007/s00228-008-0556-9&quot;>10.1007/s00228-008-0556-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18777173/&quot;>https://pubmed.ncbi.nlm.nih.gov/18777173</a></p></li><li><p>Grönlund, J, et al., &amp; Laine, K (2011). Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4. <i>Antimicrobial agents and chemotherapy</i> 55(3) 1063–1067. DOI:<a href=&quot;https://doi.org/10.1128/AAC.01242-10&quot;>10.1128/AAC.01242-10</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21173180/&quot;>https://pubmed.ncbi.nlm.nih.gov/21173180</a></p></li><li><p>Cardot, JM, et al., &amp; Aiache, JM (2004). Comparison of the pharmacokinetics of miconazole after administration via a bioadhesive slow release tablet and an oral gel to healthy male and female subjects. <i>British journal of clinical pharmacology</i> 58(4) 345–351. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.2004.02154.x&quot;>10.1111/j.1365-2125.2004.02154.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15373926/&quot;>https://pubmed.ncbi.nlm.nih.gov/15373926</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A01AB09;
